Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8059298 | 1.00 | CYP2C19 (0.53) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL5161045 | 1.00 | CYP2C19 (0.53) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL9003499 | 0.87 | CYP2C19 (0.55) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL9292311 | 0.84 | CYP2C19 (0.50) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL252677 | 0.84 | CYP2C19 (0.50) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL28548984 | 0.81 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL1610252 | 0.81 | CYP2C19 (0.50) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL17731120 | 0.80 | CYP2C19 (0.42) | CYP2C19SMN1; SMN2ALDH1A1TRPA1GABBR2 | |
| SCHEMBL10366932 | 0.80 | ACP3 (0.39) | CYP2C19ALDH1A1ATML3MBTL1 | |
| SCHEMBL7092137 | 0.80 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP2C19 4259/4885SMN1; SMN2 1807/4885ALDH1A1 1891/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CYP2C19 4259/4885SMN1; SMN2 1807/4885ALDH1A1 1891/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP2C19 4259/4885SMN1; SMN2 1807/4885ALDH1A1 1891/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CYP2C19 4259/4885SMN1; SMN2 1807/4885ALDH1A1 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.